Five Prime Therapeutics (FPRX) Tops Q3 EPS by 6c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.93), $0.06 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $4.9 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• RadNet (RDNT) Tops Q2 EPS by 9c; offers guidance
• Entera Bio Ltd. (ENTX) Misses Q2 EPS by 5c
• Caledonia Mining Corporation Plc (CMCL) Tops Q2 EPS by 89c